Focused On-demand Library for Kv channel-interacting protein 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q6PIL6

UPID:

KCIP4_HUMAN

Alternative names:

A-type potassium channel modulatory protein 4; Calsenilin-like protein; Potassium channel-interacting protein 4

Alternative UPACC:

Q6PIL6; Q3YAB8; Q3YAB9; Q3YAC0; Q3YAC1; Q3YAC2; Q4W5G8; Q8NEU0; Q9BWT2; Q9H294; Q9H2A4

Background:

Kv channel-interacting protein 4, also known as A-type potassium channel modulatory protein 4, plays a crucial role in modulating the density, inactivation kinetics, and recovery rate from inactivation of Kv4/D-type voltage-gated rapidly inactivating A-type potassium channels. This modulation is calcium-dependent and varies with the isoform of the protein. Notably, isoform 4 has a unique function in retaining KCND3 in the endoplasmic reticulum, thereby regulating its expression on the cell membrane.

Therapeutic significance:

Understanding the role of Kv channel-interacting protein 4 could open doors to potential therapeutic strategies. Its intricate involvement in modulating potassium channel activity highlights its potential as a target for developing treatments for conditions associated with potassium channel dysfunctions.